论文部分内容阅读
目的:观察病炎清I号在体外抗甲型流感病毒的作用。方法:以MDCK细胞为病毒宿主,测定病炎清I号抑制甲型流感病毒引起MDCK细胞的病变程度。并设中药对照组清开灵注射液和西药对照组病毒唑。结果:病炎清I号在1:108(相当于生药15.0 mg/ml)稀释度时达到TD50,在1:324(相当于生药5.0 mg/ml)稀释度时达到TD0和IC50,SI=3.0。清开灵注射液在1:20.78稀释度时达到TD50,在1∶36稀释度时达到TD0;在1∶47.6稀释度时达到IC50,SI=2.29。病毒唑对甲型流感病毒的半数抑制浓度IC50=6.2μg/ml。结论:病炎清I号对甲型流感病毒所致的细胞病变有一定的抑制作用,远比中药对照组清开灵注射液好,但效果不及西药对照组病毒唑。
Objective: To observe the effect of Suiyanqing I on influenza A virus in vitro. METHODS: MDCK cells were used as virus hosts to determine the severity of disease caused by Influenza A virus in MDCK cells. The Chinese medicine control group Qingkailing injection and western medicine control group ribavirin were set up. RESULTS: SJM I reached TD50 at a dilution of 1:108 (equivalent to 15.0 mg/ml of crude drug) and reached TD0 and IC50 at a dilution of 1:324 (equivalent to 5 mg/ml of crude drug). SI=3.0 . Qingkailing injection reached TD50 at 1:20.78 dilution, reached TD0 at 1:36 dilution, and reached IC50 at 1:47.6 dilution, SI=2.29. The half inhibitory concentration of ribavirin against influenza A virus IC50=6.2 μg/ml. Conclusion: Sick Yanqing I had a certain inhibitory effect on the cytopathic effect caused by influenza A virus, which was far better than the traditional Chinese medicine control group Qingkailing injection, but the effect was lower than that of western medicine control group ribavirin.